Michael Graziano is joining TARA Biosystems to become the New York company’s chief scientific officer. TARA Biosystems is developing “heart-on-a-chip” tissue models that can be used in drug discovery and drug toxicity testing. Graziano most recently worked at South San Francisco, CA-based MyoKardia (NASDAQ: [[ticker:MYOK]]), where he was vice president of research biology. Before MyoKardia, Graziano was executive director of cardiovascular research at Merck (NYSE: [[ticker:MRK]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
